2024. Long-Term Maintenance of Optimal Treatment Targets for Skin and Itch Outcomes With Upadacitinib in Moderate-to-Severe Atopic Dermatitis: 140-Week Results From the Phase 3 Measure Up 1 and 2 Studies. SKIN The Journal of Cutaneous Medicine. 8, 6 (Nov. 2024), s449. DOI:https://doi.org/10.25251/skin.8.supp.449.